APJ Agonist (Apelin Receptor Program)
Exercise mimetic targeting the apelin receptor for obesity treatment with potential to double weight loss
Other · OtherCompany source
Company profile
About BioAge
BioAge Labs researches molecular pathways that contribute to aging with an AI-driven platform to extend the human healthspan.
Company description BioAge official website
Mission. We are harnessing the biology of human aging to develop new therapies for metabolic diseases.
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Work at BioAge?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cardiovascular risk
- Chronic inflammation
- Metabolic diseases
- Metabolic dysfunction
- Obesity
Who it serves
- Healthcare providers
- Patients
- Pharma
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Positive Phase 1 data for BGE-102 reported April 2026. Completed upsized $115M public offering January 2026. Full Phase 1 data anticipated first half 2026. IND submission for APJ program anticipated by 2026 year end.
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
BGE-102
Oral NLRP3 inhibitor targeting chronic inflammation linked to cardiovascular risk and metabolic dysfunction
Other · OtherCompany source
BioAge Discovery Platform
Human-first discovery platform analyzing multi-omics data to identify molecular mediators of aging and disease
Platform · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Target identification and assessment in the era of AI.Nature reviews. Drug discovery · Jul 1, 2026
Toward actionable interventions in human aging (12th ARDD meeting, 2025).Aging · Apr 6, 2026
Recommendations for biomarker data collection in clinical trials by longevity biotechnology companies.npj aging · Dec 23, 2025
Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action.The Journal of experimental medicine · Nov 3, 2025
How to facilitate seamless translation from basic concepts to new heart failure drugs. A scientific statement of the Heart Failure Association of the ESC.European journal of heart failure · Aug 1, 2025
A Standardized Protocol for Mouse Longevity Studies in Preclinical Drug Development.Aging and disease · Jun 2, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Best-in-class reductions in hsCRP
BGE-102 Phase 1 data
Double weight loss potential
APJ agonism in preclinical obesity models
Full restoration of body composition
APJ on incretin background in preclinical models
BGE-102 Phase 1 Clinical Trial
Evaluation of oral NLRP3 inhibitor for reducing inflammation markers associated with cardiovascular risk
Potential best-in-class reductions in hsCRP (high-sensitivity C-reactive protein)
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from BioAge
Recent articles published on BioAge's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.